International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases

Giuseppe Di Iorio 1 , Matteo Lupi 1 , Fabiola Sarchione 1 , Ilaria Matarazzo 1 , Rita Santacroce 1 , Filippo Petruccelli 2 , Giovanni Martinotti 1 , * and Massimo Di Giannantonio 1
Authors Information
1 Department of Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
2 Department of Human, Social and Health Sciences, University of Cassino, Cassino, Italy
Article information
  • International Journal of High Risk Behaviors and Addiction: December 01, 2013, 2 (3); 100-106
  • Published Online: December 14, 2013
  • Article Type: Review Article
  • Received: November 21, 2012
  • Revised: April 19, 2013
  • Accepted: May 27, 2013
  • DOI: 10.5812/ijhrba.9222

To Cite: Di Iorio G, Lupi M, Sarchione F, Matarazzo I, Santacroce R, et al. The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases, Int J High Risk Behav Addict. 2013 ; 2(3):100-106. doi: 10.5812/ijhrba.9222.

Copyright © 2013, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Objectives
3. Materials and Methods
5. Conclusions
  • 1. Peters H, Nahas GG. Marihuana and medicine 1999; : 3-7
  • 2. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366(9497): 1640-9[DOI][PubMed]
  • 3. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4(11): 873-84[DOI][PubMed]
  • 4. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004; 141(5): 765-74[DOI][PubMed]
  • 5. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006; 27(1): 73-100[DOI][PubMed]
  • 6. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006; 39(4): 421-9[PubMed]
  • 7. Serra G, Bogliolo V, Garzia A, Zazzara F, Koukopoulos A, Demontis F. The role of the endocannabinoid system in the pathophysiology of mood disorders. J Psychopathol. 2011; 17: 78-91
  • 8. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3(9): 771-84[DOI][PubMed]
  • 9. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002; 54(2): 161-202[PubMed]
  • 10. Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage. 2001; 14(6): 1463-8[DOI][PubMed]
  • 11. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997; 77(2): 299-318[PubMed]
  • 12. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005; 310(5746): 329-32[DOI][PubMed]
  • 13. Luchicchi A, Pistis M. Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol. 2012; 46(2): 374-92[DOI][PubMed]
  • 14. Coraddu F, Sawcer S, Feakes R, Chataway J, Broadley S, Jones HB, et al. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics. 1998; 2(1): 24-33[PubMed]
  • 15. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev. 1993; 6(4): 382-427[PubMed]
  • 16. Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, Martin ER, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet. 1998; 7(8): 1229-34[PubMed]
  • 17. Correa F, Mestre L, Molina-Holgado E, Arevalo-Martin A, Docagne F, Romero E, et al. The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev Med Chem. 2005; 5(7): 671-5[PubMed]
  • 18. Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol. 2005; 145(4): 441-8[DOI][PubMed]
  • 19. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 1989; 23(1): 73-81[PubMed]
  • 20. Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007; 27(9): 2396-402[DOI][PubMed]
  • 21. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci. 2002; 22(22): 9742-53[PubMed]
  • 22. Cabral GA, Harmon KN, Carlisle SJ. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol. 2001; 493: 207-14[DOI][PubMed]
  • 23. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci. 2003; 23(16): 6470-4[PubMed]
  • 24. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000; 225(1): 1-8[PubMed]
  • 25. La Spada AR. Huntington's disease and neurogenesis: FGF-2 to the rescue? Proc Natl Acad Sci USA. 2005; 102(50): 17889-90[DOI][PubMed]
  • 26. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000; 97(3): 505-19[PubMed]
  • 27. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 1988; 85(15): 5733-7[PubMed]
  • 28. Allen KL, Waldvogel HJ, Glass M, Faull RL. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat. 2009; 37(4): 266-81[DOI][PubMed]
  • 29. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain. 2009; 132: 3152-64[DOI][PubMed]
  • 30. Battista N, Bari M, Tarditi A, Mariotti C, Bachoud-Levi AC, Zuccato C, et al. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis. 2007; 27(1): 108-16[DOI][PubMed]
  • 31. Molecular impacts of chronic cannabinoid treatment in Huntington's disease transgenic mice 19th Annual Symposium of the International Cannabinoid Research Society
  • 32. Sagredo O, Gonzalez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia. 2009; 57(11): 1154-67[DOI][PubMed]
  • 33. Hohmann AG, Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse. 2000; 37(1): 71-80[DOI][PubMed]
  • 34. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience. 2002; 109(3): 451-60[PubMed]
  • 35. Cadogan AK, Alexander SP, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem. 1997; 69(3): 1131-7[PubMed]
  • 36. Meschler JP, Howlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology. 2001; 40(7): 918-26[PubMed]
  • 37. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005; 67(5): 1697-704[DOI][PubMed]
  • 38. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci. 2004; 24(18): 4393-400[DOI][PubMed]
  • 39. Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem. 2006; 98(2): 408-19[DOI][PubMed]
  • 40. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999; 2(4): 358-63[DOI][PubMed]
  • 41. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003; 18(6): 1607-14[PubMed]
  • 42. Hurley MJ, Mash DC, Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm. 2003; 110(11): 1279-88[DOI][PubMed]
  • 43. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001; 14(11): 1827-32[PubMed]
  • 44. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol. 2005; 57(5): 777-9[DOI][PubMed]
  • 45. Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004; 27(3): 108-10[PubMed]
  • 46. Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther. 2007; 323(1): 318-26[DOI][PubMed]
  • 47. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 2005; 19(9): 1140-2[DOI][PubMed]
  • 48. Morgese MG, Cassano T, Gaetani S, Macheda T, Laconca L, Dipasquale P, et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int. 2009; 54(1): 56-64[DOI][PubMed]
  • 49. Marchalant Y, Baranger K, Wenk GL, Khrestchatisky M, Rivera S. Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? J Neuroinflammation. 2012; 9: 10[DOI][PubMed]
  • 50. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003; 64 Suppl 9: 7-10[PubMed]
  • 51. Downer EJ. Cannabinoids and innate immunity: taking a toll on neuroinflammation. Sci World J 2011; 11: 855-65[DOI][PubMed]
  • 52. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci. 2011; 34(6): 304-15[DOI][PubMed]
  • 53. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25(8): 1904-13[DOI][PubMed]
  • 54. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003; 23(35): 11136-41[PubMed]
  • 55. Fowler CJ, Holt S, Nilsson O, Jonsson KO, Tiger G, Jacobsson SO. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav. 2005; 81(2): 248-62[DOI][PubMed]
  • 56. Marchalant Y, Brothers HM, Wenk GL. Inflammation and aging: can endocannabinoids help? Biomed Pharmacother. 2008; 62(4): 212-7[DOI][PubMed]
  • 57. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2007; 5(2): 73-80[PubMed]
  • 58. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation. 2005; 2: 29[DOI][PubMed]
  • 59. Tolon RM, Nunez E, Pazos MR, Benito C, Castillo AI, Martinez-Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009; 1283: 148-54[DOI][PubMed]
  • 60. Nicholson SJ, Witherden AS, Hafezparast M, Martin JE, Fisher EM. Mice, the motor system, and human motor neuron pathology. Mamm Genome. 2000; 11(12): 1041-52[PubMed]
  • 61. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS-what is the evidence? J Neurol. 2000; 247 Suppl 1-16[PubMed]
  • 62. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol. 2000; 247 Suppl 1-6[PubMed]
  • 63. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001; 2(11): 806-19[DOI][PubMed]
  • 64. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006; 6: 12[PubMed]
  • 65. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(1): 33-9[DOI][PubMed]
  • 66. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006; 20(7): 1003-5[DOI][PubMed]
  • 67. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003; 23(4): 1398-405[PubMed]
  • 68. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004; 65(4): 999-1007[DOI][PubMed]
  • 69. Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006; 542(1-3): 100-5[DOI][PubMed]
  • 70. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007; 101(1): 87-98[DOI][PubMed]
  • 71. Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2001; 18(4): 264-70[PubMed]
  • 72. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004; 141(5): 775-85[DOI][PubMed]
  • 73. Martinotti G, Di Iorio G, Sepede G, De Berardis D, De Risio L, Di Giannantonio M. Cannabis use and psychosis: theme introduction. Curr Pharm Des. 2012; 18(32): 4991-8[PubMed]
  • 74. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry. 2011; 2: 10[DOI][PubMed]
  • 75. Martinotti G, Di lorio G, Tedeschi D, De Berardis D, Niolu C, Janiri L, et al. Prevalence and intensity of basic symptoms among cannabis users: an observational study. Am J Drug Alcohol Abuse. 2011; 37(2): 111-6[DOI][PubMed]
  • 76. Cuomo C, Sarchiapone M, Giannantonio MD, Mancini M, Roy A. Aggression, impulsivity, personality traits, and childhood trauma of prisoners with substance abuse and addiction. Am J Drug Alcohol Abuse. 2008; 34(3): 339-45[DOI][PubMed]
  • 77. Martinotti G, Carli V, Tedeschi D, Di Giannantonio M, Roy A, Janiri L, et al. Mono- and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses. Addict Behav. 2009; 34(9): 790-3[DOI][PubMed]
  • 78. Sarchiapone M, Carli V, Giannantonio MD, Roy A. Risk factors for attempting suicide in prisoners. Suicide Life Threat Behav. 2009; 39(3): 343-50[DOI][PubMed]
  • 79. Schifano F, Leoni M, Martinotti G, Rawaf S, Rovetto F. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol Behav. 2003; 6(4): 405-10[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments